Skip to main content

Table 4 Treatment modalities and outcome of patients with PD at 9–12 months after initial therapy and at last follow-up visit according to tumor burden

From: Tumor burden of persistent disease in patients with differentiated thyroid cancer: correlation with postoperative risk-stratification and impact on outcome

   9–12 months after initial therapy   At last follow-up visit
Very small-volume PD (n = 24) Small-volume PD
(n = 25)
Large-volume PD
(n = 58)
p Very small-volume PD (n = 24) Small-volume PD
(n = 25)
Large-volume PD
(n = 58)
p
Treatment modalitiesa
 RAI 24 (100%) 25 (100%) 58 (100%)   10 (40%) 4 (16%) 19 (33%)  
 Neck surgery 0 2 (8%) 22 (39%)   0 5 (20%) 17 (30%)  
 Neck external radiation beam therapy 0 0 7 (12%)   0 1 (4%) 6 (11%)  
 Local treatment of DMb 0 0 7 (12%)   0 2 (8%) 13 (23%)  
 Tyrosine-kinase inhibitors 0 0 0   0 1 (4%) 12 (21%)  
 Chemotherapy 0 0 0   0 0 1 (2%)  
Outcome     < 0.0001     0.0003
 Excellent response 17 (71%) 5 (20%) 4 (7%)   18 (75%) 7(28%) 9 (16%)  
 Indeterminate response 2 (8%) 6 (24%) 3 (5%)   2 (8%) 6 (24%) 10 (17%)  
 Biochemical incomplete response 2 (8%) 3 (12%) 3 (5%)   3 (13%) 4 (16%) 10 (17%)  
 Structural incomplete response 3 (13%) 11 (44%) 48 (83%)   1 (4%) 8 (32%) 29 (50%)  
  1. a Treatment modalities at 9–12 months after initial therapy: treatments given within the first year of follow-up; treatment modalities at last follow-up visit: treatments given after the first year during follow-up
  2. b Local treatment of DM: external radiation beam therapy, surgery or radiofrequency
  3. Abbreviations: PD Persistent disease; RAI Radioiodine; DM Distant metastases